Loading
Radiomics and Machine Learning in Medical Imaging / Ai in Cancer Detection / Endometrial and Cervical Cancer Treatments · Review
Frontiers in Oncology · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a structured narrative review that synthesizes the current state of AI applications in endometrial cancer diagnosis and prognosis, including deep learning, digital pathology, and radiomics. The authors report that recent multimodal frameworks such as HECTOR have shown improved prognostic performance in externally validated cohorts for predicting distant recurrence, but acknowledge that current evidence is limited by retrospective designs, small datasets, potential overfitting, and insufficient prospective validation.
Structured narrative review. Endometrial cancer patients; review also contextualizes rising incidence driven by obesity, metabolic syndrome, diabetes mellitus, and aging populations.
Multimodal deep-learning models, particularly HECTOR, have demonstrated improved prognostic performance compared with conventional clinicopathologic risk-stratification systems for predicting distant recurrence in externally validated cohorts AI systems can differentiate benign from malignant lesions, predict myometrial invasion and lymph node metastases, stratify recurrence risk, and support individualized therapeutic decision-making Current evidence is limited by predominantly retrospective study designs, relatively small and frequently imbalanced datasets, potential overfitting, heterogeneous imaging protocols, limited external validation, and insufficient prospective clinical evidence
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While AI applications show promise in improving prognostic stratification for endometrial cancer, clinicians should be cautious about adopting these tools pending prospective validation, as the source explicitly states that further prospective validation remains necessary and current evidence remains limited by retrospective designs and small datasets.
This is a narrative review synthesizing existing literature on AI applications in endometrial cancer; it does not report original empirical results, primary endpoints, or comparative efficacy data from controlled studies, and explicitly acknowledges that prospective clinical evidence remains insufficient.
As stated by the source record.
While AI applications show promise in improving prognostic stratification for endometrial cancer, clinicians should be cautious about adopting these tools pending prospective validation, as the source explicitly states that further prospective validation remains necessary and current evidence remains limited by retrospective designs and small datasets.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with a rising incidence driven by obesity, metabolic syndrome, diabetes mellitus, and aging populations. Artificial intelligence (AI) has rapidly advanced in gynecologic oncology, particularly in diagnostic imaging, digital pathology, radiomics, and multimodal prognostic modeling. Recent breakthroughs in machine learning, deep learning, and whole-slide imaging (WSI), including multimodal prognostic architectures such as HECTOR and explainable AI (XAI), have enabled the development of sophisticated diagnostic and prognostic systems. These systems can differentiate benign from malignant lesions, predict myometrial invasion and lymph node metastases, stratify recurrence risk, and support individualized therapeutic decision-making. Notably, recent multimodal deep-learning models, particularly the HECTOR framework, have demonstrated improved prognostic performance compared with conventional clinicopathologic risk-stratification systems for predicting distant recurrence in externally validated cohorts, although further prospective validation remains necessary. Despite these promising advances, current evidence remains limited by predominantly retrospective study designs, relatively small and frequently imbalanced datasets, potential overfitting of AI models, heterogeneous imaging protocols, limited external validation, and insufficient prospective clinical evidence. These limitations restrict model generalizability across different populations and healthcare settings. Furthermore, ethical, regulatory, and data-governance challenges remain important barriers to widespread clinical implementation. This structured narrative review summarizes AI applications in endometrial cancer, focusing on ultrasound imaging, radiomics, digital pathology, multimodal deep-learning, explainable AI, prognostic modeling, clinical translation, and future perspectives in personalized care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.